FDA Greenlights Bi-Annual HIV Injection by Gilead: A Game-Changer in Prevention
The Food and Drug Administration has taken a significant step by approving a twice-yearly injectable drug designed by Gilead to combat HIV—marking a pivotal advancement in the bid to end the persistent epidemic.
Despite this promising development, the rollout of this injection, known as lenacapavir, is not without challenges. Concerns arise from the Trump administration's proposed cuts to federal HIV prevention funding, which could impede accessibility.
In a pair of landmark studies conducted last year, lenacapavir demonstrated remarkable efficacy, almost completely preventing new HIV infections when administered biannually. This approach requires far fewer doses compared to daily preventive pills or bi-monthly injections already available.
Lenacapavir is a pivotal tool in mitigating an epidemic responsible for millions of infections and over half a million deaths globally in 2023, as noted by the World Health Organization.
Barriers to Accessibility
As of now, approximately 700 new HIV cases surface weekly in the United States alone, alongside 100 deaths linked to the virus, Gilead's CEO Daniel O'Day highlighted in a discussion preceding the drug's approval. Marginalized groups, including people of color and the LGBTQ+ community, are disproportionately affected.
"The potential impact on global health cannot be overstated," remarked O'Day, emphasizing the injection's promise in reversing the epidemic's trajectory once distributed worldwide.
Jeremiah Johnson, at the helm of an organization advocating broader access to HIV prevention drugs, stresses that the product's accessibility will significantly influence its success.
Financial Considerations and Market Projections
Lenacapavir is also approved for HIV treatment as Sunlenca, priced over $42,000 annually. 2024 reports suggest production costs could be significantly lower, potentially at $26 to $40 yearly.
The injection's pricing strategy remains undisclosed by Gilead but is expected to align with existing preventive options. Analysts from Mizuho predict that global sales could hit $4 billion, balancing both treatment and prevention uses.
Gilead pledges to provide the injection across various nations, acknowledging that HIV knows no borders. Agreements in over 120 low-income nations will allow for lower-cost versions to be produced and distributed.
The company has further vowed to offer doses to up to 2 million beneficiaries at no profit until lower-cost versions are available.
Tackling Stigma and Enhancing Education
For a decade, PrEP was only available in daily pill form, yet new infection rates have remained stagnant, particularly due to the difficulty in maintaining a consistent medication routine amid stigma and challenges within certain communities.
Disproportionate access issues persist, with Black Americans forming 43% of new diagnoses but only 14% of PrEP users, and similar disparities among Hispanic populations.
Gilead's Chief Commercial Officer Johanna Mercier recognizes these challenges and points to the privacy offered by a semi-annual injection as a critical advantage, enhancing uptake among new demographics.
She asserts that awareness campaigns are paramount to highlighting lenacapavir's convenience and efficacy, specifically aimed at those not previously engaged with PrEP.
Effectiveness Backed by Trials
A pivotal study involving diverse participants — like transgender and nonbinary individuals — showed nearly 100% success in preventing infections, signifying a major advancement over existing treatments.
A separate study focusing on cisgender women reflected similar effectiveness, achieving full prevention of HIV infections among those receiving the injection.
Navigating Political and Economic Threats
In the U.S., reaching underserved communities will necessitate comprehensive insurance backing. While commercial insurance predominates among PrEP users, Medicaid's role in supporting low-income populations is critical.
Medicaid insures the largest segment of HIV-positive individuals in America, according to KFF, rendering Republican proposals to curtail Medicaid funding a significant threat to those relying on these services.
While Gilead is optimistic about Medicaid's continued support, Mercier underscores the importance of protective measures across government programs to safeguard access for both treatment and prevention.
Jeremiah Johnson warns that proposed federal budget reductions could severely disrupt HIV prevention infrastructure, jeopardizing efforts to distribute the new injection through necessary channels.
Federal plans include drastic reductions to critical CDC programs in charge of prevention, echoing a need for Congress’s intervention to avoid rising infections should public health infrastructure falter.



Leave a Reply